Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Emerg Infect Dis ; 26(11): 2586-2590, 2020 11.
Article in English | MEDLINE | ID: mdl-33079040

ABSTRACT

The Federal Select Agent Program dictates that all research entities in the United States must rigorously assess laboratory protocols to sterilize samples being removed from containment areas. We validated procedures using sterile filtration and methanol to remove the following select agents: Francisella tularensis, Burkholderia pseudomallei, B. mallei, Yersinia pestis, and Bacillus anthracis. We validated methanol treatment for B. pseudomallei. These validations reaffirm safety protocols that enable researchers to keep samples sufficiently intact when samples are transferred between laboratories.


Subject(s)
Containment of Biohazards/standards , Laboratories/standards , Bacillus anthracis , Burkholderia mallei , Burkholderia pseudomallei , Francisella tularensis , Sterilization , Yersinia pestis
2.
Antimicrob Agents Chemother ; 60(3): 1834-40, 2016 Jan 11.
Article in English | MEDLINE | ID: mdl-26824958

ABSTRACT

The objective of this study was to evaluate the natural history and pathogenesis of Francisella tularensis in a murine model of inhalational tularemia with the SchuS4 strain. Before the efficacy of antimicrobials could be assessed in this model, further model development was required to determine the optimal time to start therapy. This study helped define the time course of infection after aerosol challenge by quantifying the presence of bacteria in lung, blood, and spleen at multiple harvest points. In this study, mice were infected via a targeted inhaled dose of 100 50% lethal doses (LD50s) (LD50 = 300 CFU) of F. tularensis by whole-body aerosol. At 1, 24, 36, 48, 60, 72, 75, 78, 81, 84, 87, and 90 h postchallenge, groups of 15 animals were sacrificed and blood, lung, and splenic tissue samples were harvested, homogenized, plated, and incubated to evaluate the bacterial load in those tissues. It was determined that of the 3 sample types harvested, splenic tissue provided the most consistent bacterial counts, which steadily increased with the progressing infection. Further, it was determined that lung samples from all (15/15) animals were positive for infection at 75 h postaerosolization and that 14/15 animals had positive splenic tissue counts. Bacterial levels in blood were not predictive of treatment initiation. For future therapeutic evaluation studies in this model using F. tularensis (SchuS4), it was determined that therapy should be initiated at 75 h postchallenge and validated by spleen involvement.


Subject(s)
Bacteremia/microbiology , Francisella tularensis/pathogenicity , Lung/microbiology , Spleen/microbiology , Tularemia/pathology , Aerosols , Animals , Bacterial Load , Disease Models, Animal , Disease Progression , Female , Mice , Mice, Inbred BALB C , Models, Theoretical
3.
J Med Microbiol ; 64(6): 646-653, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25850696

ABSTRACT

Burkholderia mallei is a Gram-negative bacillus that causes a pneumonic disease known as glanders in equids and humans, and a lymphatic infection known as farcy, primarily in equids. With the potential to infect humans by the respiratory route, aerosol exposure can result in severe, occasionally fatal, pneumonia. Today, glanders infections in humans are rare, likely due to less frequent contact with infected equids than in the past. Acutely ill humans often have non-specific clinical signs and in order to diagnose cases, especially in scenarios of multiple cases in an unexpected setting, rapid diagnostics for B. mallei may be critical. The pathogenesis of acute glanders in the rhesus macaque (Macaca mulatta) was studied as an initial effort to improve diagnostic methods. In the study described here, the diagnostic techniques of PCR, culture and histopathology were compared. The results indicated that PCR may provide rapid, non-invasive diagnosis of glanders in some cases. As expected, PCR results were positive in lung tissue in 11/12 acutely infected rhesus macaques, but more importantly in terms of diagnostic algorithm development, PCR results were frequently positive in non-invasive samples such as broncho-alveolar lavage or nasal swabs (7/12) and occasionally in blood (3/12). However, conventional bacterial culture failed to recover bacteria in many of these samples. The study showed that the clinical presentation of aerosol-exposed rhesus macaques is similar to descriptions of human glanders and that PCR has potential for rapid diagnosis of outbreaks, if not individual cases.


Subject(s)
Aerosols/administration & dosage , Burkholderia mallei/growth & development , Glanders/diagnosis , Glanders/pathology , Administration, Inhalation , Animals , Bacteriological Techniques/methods , Disease Models, Animal , Histocytochemistry/methods , Macaca mulatta , Molecular Diagnostic Techniques/methods , Pathology/methods , Polymerase Chain Reaction/methods , Sensitivity and Specificity , Time Factors
4.
J Med Microbiol ; 63(Pt 1): 118-128, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24105842

ABSTRACT

Aerosolized Burkholderia pseudomallei, the causative agent of melioidosis, can infect many species of mammals (including humans), causing rapid, severe pneumonia with high mortality. Diagnosis in humans is challenging, as few organisms can be detected in blood or other non-invasive samples. Although it cannot be said that the model is established, studies to date indicate that rhesus macaques may represent a good model of human melioidosis. This is supported by the results of this study. The early progression of meliodosis in the rhesus macaque was studied in an effort to better understand the disease and the application of rapid diagnostic methods. Results indicate that a PCR analysis of key diagnostic samples such as nasal swabs, throat swabs, tracheo bronchial lymph node aspirates and broncho-alveolar lavage may be a useful component of a rapid diagnostic algorithm in case of aerosol exposure.


Subject(s)
Aerosols/administration & dosage , Burkholderia pseudomallei/isolation & purification , Disease Models, Animal , Melioidosis/diagnosis , Melioidosis/pathology , Animals , Humans , Macaca mulatta , Polymerase Chain Reaction/methods , Respiratory System/microbiology
5.
Antimicrob Agents Chemother ; 57(5): 2010-5, 2013 May.
Article in English | MEDLINE | ID: mdl-23403418

ABSTRACT

After a relatively short untreated interval, pneumonic plague has a mortality approaching 100%. We employed a murine model of aerosol challenge with Yersinia pestis to investigate the early course of pneumonic plague in the lung, blood, and spleen. We fit a mathematical model to all data simultaneously. The model fit to the data was acceptable. The number of organisms in the lung at baseline was estimated to be 135 (median) or 1,184 (mean) CFU/g. The doubling time was estimated as 1.5 to 1.7 h. Between 1 and 12 h postexposure, counts declined, but they then increased by 24 h, a finding hypothesized to be due to innate immunity. The model predicted that innate immunity declined with a half-time of 3 to 3.8 h. The threshold for bacteremia was 6.4 × 10(4) to 1.52 × 10(6) CFU/g. By 42 to 48 h, stationary phase was obtained. Lung bacterial burdens exceeded 10 log CFU/g. Obviating early defenses allows for rapid amplification of Y. pestis in bacteremia, making the rapid course with high mortality understandable.


Subject(s)
Bacteremia/microbiology , Lung/microbiology , Models, Statistical , Plague/microbiology , Spleen/microbiology , Yersinia pestis/immunology , Aerosols , Animals , Bacteremia/immunology , Bacteremia/mortality , Colony Count, Microbial , Female , Immune Evasion , Immunity, Innate , Lung/immunology , Mice , Mice, Inbred BALB C , Plague/immunology , Plague/mortality , Spleen/immunology , Survival Analysis , Yersinia pestis/pathogenicity
6.
J Med Microbiol ; 59(Pt 6): 724-730, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20223898

ABSTRACT

The US Centers for Disease Control and Prevention lists Brucella as a potential bioterrorism threat requiring enhanced diagnostic capacity and surveillance (http://emergency.cdc.gov/bioterrorism/). Successful treatment and management of patients after exposure to biological threat agents depends on accurate and timely diagnosis, but many biothreat agents present with similar, vague clinical signs--commonly referred to as 'flu-like illness'. Diagnosis of brucellosis is notoriously challenging, especially early in infection, and definitive diagnosis may require invasive methods, e.g. bone marrow biopsy. We studied the pathogenesis of Brucella suis aerosol infection in rhesus macaques in an effort to guide the diagnostic algorithm in case of possible intentional exposure of humans. Rhesus proved to be an excellent model for human brucellosis; the data showed that PCR DNA amplification testing of non-invasive diagnostic samples has the potential to definitively detect a point-source outbreak immediately and for several days after exposure.


Subject(s)
Brucella suis/isolation & purification , Brucella suis/pathogenicity , Brucellosis/diagnosis , Brucellosis/pathology , Disease Models, Animal , Macaca mulatta/microbiology , Polymerase Chain Reaction/methods , Aerosols , Animals , DNA, Bacterial/genetics , DNA, Bacterial/isolation & purification , Humans
7.
Antiviral Res ; 61(1): 57-62, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14670594

ABSTRACT

We investigated whether crude hop extracts and purified hop components representing every major chemical class of hop compound have antiviral activity. These hop constituents were tested for antiviral activity against bovine viral diarrhea virus (BVDV) as a surrogate model of hepatitis C virus (HCV), human immunodeficiency virus (HIV), influenza A virus (FLU-A), influenza B virus (FLU-B), rhinovirus (Rhino), respiratory syncytial virus (RSV), yellow fever virus (YFV), cytomegalovirus (CMV), hepatitis B virus (HBV), and herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). The extracts all failed to prevent the replication of HIV, FLU-A, FLU-B, RSV and YFV. A xanthohumol-enriched hop extract displayed a weak to moderate antiviral activity against BVDV (therapeutic index (TI)=6.0), HSV-2 (TI=>5.3), Rhino (TI=4.0) and HSV-1 (TI=>1.9) with IC(50) values in the low microg/ml range. Pure iso-alpha-acids demonstrated low to moderate antiviral activity against both BVDV (TI=9.1) and CMV (TI=4.2) with IC(50) values in the low microg/ml range. No antiviral activity was detected using beta-acids or a hop oil extract. Ultra-pure preparations (>99% pure) were used to show that xanthohumol accounted for the antiviral activity observed in the xanthohumol-enriched hop extract against BVDV, HSV-1 and HSV-2. Xanthohumol was found to be a more potent antiviral agent against these viruses than the isomer iso-xanthohumol. With Rhino, the opposite trend was observed with iso-xanthohumol showing superior antiviral activity to that observed with xanthohumol. Xanthohumol also showed antiviral activity against CMV, suggesting that it might have a generalized anti-herpesvirus antiviral activity. Again, superior antiviral activity was observed with the xanthohumol isomer against CMV. In summary, iso-alpha-acids and xanthohumol were shown to have a low-to-moderate antiviral activity against several viruses. These hop constituents might serve as interesting lead compounds from which more active anti-HCV, anti-Rhino and anti-herpesvirus antiviral agents could be synthesized.


Subject(s)
Antiviral Agents/pharmacology , DNA Viruses/drug effects , Humulus/chemistry , Plant Extracts/pharmacology , Propiophenones/pharmacology , RNA Viruses/drug effects , Animals , Cell Line , Cytomegalovirus/drug effects , Cytomegalovirus/growth & development , DNA Viruses/growth & development , Diarrhea Viruses, Bovine Viral/drug effects , Diarrhea Viruses, Bovine Viral/growth & development , Flavonoids , Herpesvirus 1, Human/drug effects , Herpesvirus 1, Human/growth & development , Herpesvirus 2, Human/drug effects , Herpesvirus 2, Human/growth & development , Humans , RNA Viruses/growth & development , Virus Replication/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...